Hardt K - Search Results

1

Vaccine strategies: Optimising outcomes.

Hardt K, Bonanni P, King S, Santos JI, El-Hodhod M, Zimet GD, Preiss S. Hardt K, et al. Vaccine. 2016 Dec 20;34(52):6691-6699. doi: 10.1016/j.vaccine.2016.10.078. Epub 2016 Nov 23. Vaccine. 2016. PMID: 27887796 Free article. Review.

2

Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age.

Avdicova M, Crasta PD, Hardt K, Kovac M. Avdicova M, et al. Among authors: hardt k. Vaccine. 2015 May 28;33(23):2727-33. doi: 10.1016/j.vaccine.2014.06.070. Epub 2014 Jun 22. Vaccine. 2015. PMID: 24962750

3

Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.

Kovac M, Rathi N, Kuriyakose S, Hardt K, Schwarz TF. Kovac M, et al. Among authors: hardt k. Vaccine. 2015 May 21;33(22):2594-601. doi: 10.1016/j.vaccine.2015.03.104. Epub 2015 Apr 14. Vaccine. 2015. PMID: 25882172 Free article. Clinical Trial.

4

Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults.

Hens N, Habteab Ghebretinsae A, Hardt K, Van Damme P, Van Herck K. Hens N, et al. Among authors: hardt k. Vaccine. 2014 Mar 14;32(13):1507-13. doi: 10.1016/j.vaccine.2013.10.088. Epub 2014 Feb 7. Vaccine. 2014. PMID: 24508042 Clinical Trial.

5

Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.

Li R, Li CG, Li Y, Liu Y, Zhao H, Chen X, Kuriyakose S, Van Der Meeren O, Hardt K, Hezareh M, Roy-Ghanta S. Li R, et al. Among authors: hardt k. Vaccine. 2016 Mar 14;34(12):1436-43. doi: 10.1016/j.vaccine.2016.02.010. Epub 2016 Feb 9. Vaccine. 2016. PMID: 26873055 Free article. Clinical Trial.

6

Immunogenicity of Infanrix™ hexa administered at 3, 5 and 11 months of age.

Van Der Meeren O, Kuriyakose S, Kolhe D, Hardt K. Van Der Meeren O, et al. Among authors: hardt k. Vaccine. 2012 Apr 5;30(17):2710-4. doi: 10.1016/j.vaccine.2012.02.024. Epub 2012 Feb 18. Vaccine. 2012. PMID: 22349525 Clinical Trial.

7

Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines.

Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, Dubin G, Breuer T. Verstraeten T, et al. Among authors: hardt k. Vaccine. 2008 Dec 2;26(51):6630-8. doi: 10.1016/j.vaccine.2008.09.049. Vaccine. 2008. PMID: 18845199

8

Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials.

Van Damme P, McIntyre P, Grimprel E, Kuriyakose S, Jacquet JM, Hardt K, Messier M, Van Der Meeren O. Van Damme P, et al. Among authors: hardt k. Vaccine. 2011 Aug 11;29(35):5932-9. doi: 10.1016/j.vaccine.2011.06.049. Epub 2011 Jun 28. Vaccine. 2011. PMID: 21718738 Clinical Trial.

9

Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.

Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow SN, Kitchener HC, Teixeira JC, Jaisamrarn U, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Mindel A, de Sutter P, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group. Apter D, et al. Among authors: hardt k. Clin Vaccine Immunol. 2015 Apr;22(4):361-73. doi: 10.1128/CVI.00591-14. Epub 2015 Feb 4. Clin Vaccine Immunol. 2015. PMID: 25651922 Free PMC article. Clinical Trial.

10

Evaluation of a new syringe presentation of reduced-antigen content diphtheria, tetanus, and acellular pertussis vaccine in healthy adolescents--A single blind randomized trial.

Pavia-Ruz N, Abarca K, Lepetic A, Cervantes-Apolinar MY, Hardt K, Jayadeva G, Kuriyakose S, Han HH, de la O M. Pavia-Ruz N, et al. Among authors: hardt k. Hum Vaccin Immunother. 2015;11(7):1770-4. doi: 10.1080/21645515.2015.1041697. Hum Vaccin Immunother. 2015. PMID: 26075317 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

109 results

Search Page

Filters